Sars-CoV-2 circulating variants

This page describes circulating SARS-CoV-2 variants - Last update 15.03.2021

Below table in PDF:Table-Variants-SARS-CoV-2.pdf image

,
LineagesynonymsEmergenceSpike substitutionsOther substitutionsConsensus fastaPhenotypes
19AWuhan-Hu-1, nCoV China, Dec. 2019NoneNoneGenome
Spike protein
All proteins
Reference for variants
B.1.1.7
>PANGO
>BV-BRC
20I/501Y.V1,
VOC 202012/01
UK, September 2020 Del 69-70, Del 144, N501Y, A570D, D614G, P681H, T716I, S982A, D1118H orf1ab:T1001I, orf1ab:A1708D, orf1ab:I2230T, del:11288:9, del:21765:6, del:21991:3, Orf8:R52I, Orf8:Q27*, Orf8:Y73C, N:D3L, N:S235Fgenome
Spike protein
All proteins
Increased transmissibility; S gene target failure (SGTF)
B.1.351
>PANGO
>BV-BRC
20H/501Y.V2South Africa, Oct 2020 (L18F), D80A, D215G , (Del 242-244), K417N, E484K, N501Y, D614G, A701V E:P71L, N:T205I, orf1a:K1655Ngenome
Spike protein
All proteins
E484K loss of serum antibody neutralization
P.1
>PANGO
>BV-BRC
B.1.1.28.1, 20J/501Y.V3Brazil, July 2020 L18F, T20N, P26S, D138Y, R190S, K417N/T, E484K, N501Y, D614G, H655Y, T1027I, V1176Forf1ab:S1188L, orf1ab:K1795Q, del:11288:9,
orf3a:G174C, orf8:E92K
N:P80R
genome
Spike protein
All proteins
Increased transmissibility; E484K and K417 may contribute to loss of serum antibody neutralization
P.2
>PANGO
B.1.1.28.2Brasil, Oct. 2020E484K, D614G, (T859I), (V1176F)
B.1.1.318
>PANGO
Switzerland, Janv 2021T95I, DelY144, E484K, D614G, Q677H, D796H
B.1.375
>PANGO
>BV-BRC
USA, Sept 2020Del H69-V70
D614G
orf1ab:T1828A,
orf1b:E1264D,
orf3a: T151I,
M:I48V
genome
S Protein
All proteins
S gene target failure (SGTF)
B.1.427
>PANGO
California(CA)USA Sept. 2020S13I, W152C, L452R, D614Gorf1a:T265I, S3158T, orf1b:P314L, P976L, D1183Y,
orf3a:Q57H,
N:T205I
May display increased transmission and decreased neutralization by convalescent plasma and vaccines
B.1.429
>PANGO
>BV-BRC
CAL.20CCalifornia July 2020S13I, W152C, L452R, D614Gorf1a:T265I, I4205V, orf1b:P314L, D1183Y,
orf3a:Q57H,
N:T205I
genome
Spike protein
All proteins
May display increased transmission and decreased neutralization by convalescent plasma and vaccines
B.1.525
>PANGO
Worldwide Dec.2020 Q52R, E484K, D614G, Q677H, F888L orf1ab:L4715F, E:L21F, E:I82T, del:11288:9, del:21765:6, del:28278:3
B.1.526
>PANGO
USA Sept 2020L5F, T95I, D253G, (S477N), (E484K), D614G, A701V
B.1.177
>PANGO
20A.EU1Europe, Jul. 2020A222V, D614G
B1.?20A.EU2Europe; Jun. 2020S477N, D614GMay increase resistance to mAb
A.23.1
>PANGO
Uganda Oct.2020(R102I), F157L, V367F, Q613H, (P681R)nsp3: E95K, nsp6: M86I, L98F, ORF 8: L84S, E92K and ORF9 N: S202N, Q418H

Sources: Vipr variants of concern
PANGO lineages
Societe Francaise de Microbiologie, Variants
The Variant Gambit: COVID?s Next Move